구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes |
Overview Company | Mustang Bio, Inc. |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) and evade immune clearance |
MoA Mechanism | targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway |
MoA Biomarker | biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Toxicology CRS | Reported |
Clinical Safety signal | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes |
Overview Company | Mustang Bio, Inc. |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) and evade immune clearance |
MoA Mechanism | targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway |
MoA Biomarker | biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Toxicology CRS | Reported |
Clinical Safety signal | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교